CSL News: CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack P - 27th Feb 2023, 2:45am

[annb0t]

Majority of patients were attack free during the entire six-month treatment period (61.5%) Study results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions anticipated later in the calendar year Garadacimab underscores CSL's promise to develop innovative medicines for people living with rare diseases like HAE, a community CSL has been serving for 40 years

KING OF PRUSSIA, Pa., Feb. 26, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOT...

>>> Read more: CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing